[1]曹绪深.稳心调脂汤对冠心病合并高脂血症患者中医证候及血脂水平的影响[J].医学信息,2020,33(07):160-161.[doi:10.3969/j.issn.1006-1959.2020.07.053]
　CAO Xu-shen.Effect of Wenxin Tiaozhi Decoction on TCM Syndromes and Blood Lipid Levels in Patients with Coronary Heart Disease and Hyperlipidemia[J].Medical Information,2020,33(07):160-161.[doi:10.3969/j.issn.1006-1959.2020.07.053]
点击复制

稳心调脂汤对冠心病合并高脂血症患者中医证候及血脂水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年07期
页码:
160-161
栏目:
中医中药
出版日期:
2020-04-01

文章信息/Info

Title:
Effect of Wenxin Tiaozhi Decoction on TCM Syndromes and Blood Lipid Levels in Patients with Coronary Heart Disease and Hyperlipidemia
文章编号:
1006-1959（2020）07-0160-03
作者:
曹绪深
（天津市静海区中医医院内三科，天津 301600）
Author(s):
CAO Xu-shen
(Department of Internal Medicine,Subject Three,Jinghai District Traditional Chinese Medicine Hospital,Tianjin 301600,China)
关键词:
稳心调脂汤; 冠心病; 高脂血症; 中医证候; 血脂水平
Keywords:
Wenxin Tiaozhi Decoction; Coronary heart disease; Hyperlipidemia; TCM syndromes; Blood lipid levels
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2020.07.053
文献标志码:
A
摘要:
目的 研究稳心调脂汤治疗冠心病合并高脂血症对中医证候及血脂水平的影响。方法 选取2018年1月~2019年7月在我院诊治的88例冠心病合并高脂血症患者为研究对象，采用随机数字表法分为对照组和观察组，各44例。对照组采用阿司匹林联合富马酸比索洛尔治疗，观察组在对照组基础上联合稳心调脂汤治疗，比较两组临床治疗总有效率、血脂[血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）]水平、中医证候积分及安全性。结果 观察组治疗总有效率为95.45%，高于对照组的81.81%，差异有统计学意义（P＜0.05）；治疗后两组TC、TG、LDL-C均低于治疗前，且观察组低于治疗组，差异有统计学意义（P＜0.05）；治疗后两组HDL-C均高于治疗前，且观察组高于对照组，差异有统计学意义（P＜0.05）；治疗后两组胸闷、胸痛、心悸、气促、疲倦乏力证候积分均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组不良反应发生率为2.27%与对照组的4.54%比较，差异无统计学意义（P＞0.05）。结论 稳心调脂汤可提高对冠心病合并高脂血症临床治疗疗效，改善血脂水平，减轻中医证候，且应用不良反应少，值得临床应用。
Abstract:
Objective To study the effect of Wenxin Tiaozhi Decoction on coronary heart disease with hyperlipidemia on TCM syndromes and blood lipid levels. Methods A total of 88 patients with coronary heart disease and hyperlipidemia diagnosed and treated in our hospital from January 2018 to July 2019 were selected as the research object. They were divided into a control group and an observation group with a random number table method, 44 cases each. The control group was treated with aspirin and bisoprolol fumarate, and the observation group was combined with Wenxin Tiaozhi Decoction on the basis of the control group. The total clinical efficacy, serum lipids [serum total cholesterol (TC),Triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C)] levels, TCM syndrome scores and safety. Results The total effective rate of treatment in the observation group was 95.45%, which was higher than 81.81% in the control group, the difference was statistically significant (P<0.05); after treatment, the TC, TG, LDL-C of the two groups were lower than before treatment, and the observation group was low In the treatment group, the difference was statistically significant (P<0.05); after treatment, the HDL-C in both groups was higher than before treatment, and the observation group was higher than the control group, the difference was statistically significant (P<0.05); two after treatment The syndrome scores of chest tightness, chest pain, palpitations, shortness of breath, fatigue and fatigue were lower than before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05); the incidence of adverse reactions in the observation group was 2.27% and compared with 4.54% of the control group, the difference was not statistically significant (P>0.05).Conclusion Wenxin Tiaozhi Decoction can improve the curative effect of coronary heart disease combined with hyperlipidemia, improve the level of blood lipids, reduce the symptoms of traditional Chinese medicine, and have fewer adverse reactions.

参考文献/References:

[1]梁嘉晖,胡经航,韦继政,等.瑞舒伐他汀治疗老年冠状动脉性心脏病合并高脂血症的机制研究[J].重庆医学,2016,45(1):112-114. [2]中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南修订版[J].中国循环杂志,2016,31(10):937-947. [3]郭丽丽,王阶.中医药防治冠心病的特色和优势分析[J].时珍国医国药,2016,27(10):2464-2465. [4]方利华.瑞舒伐他汀对冠心病合并高脂血症老年患者血脂水平和炎症因子影响的临床研究[J].中国现代医学杂志,2014,21(36):43-46. [5]朱云仙,李敏.“瘀热相搏”理论与急性冠脉综合征发病机制探讨[J].江苏中医药,2017,49(3):9-11. [6]赵浩,刘剑刚,雷燕.血脂异常血瘀证患者血液流动性和流变性观察[J].微循环学杂志,2015,25(3):23-26. [7]赵永见,牛凯,唐德志,等.桃仁药理作用研究近况[J].辽宁中医杂志,2015,42(4):888-890. [8]杨月花,张堪宝,郑冬冬.天灸治疗精神分裂症患者痰瘀互结型血脂异常的临床观察[J].世界中西医结合杂志,2017,12(5):691-693. [9]乐世俊,唐于平,王林艳,等.红花中黄酮类化合物的分离与体外抗氧化研究[J].中国中药杂志,2014,39(17):3295-3300. [10]成仁,李磊,任建勋,等.痰瘀同治方对小型猪痰瘀互结证冠心病血液流变性及血脂的改善作用[J].中国中药杂志,2014,39(2):300-303.

相似文献/References:

[1]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Medical Information,2018,31(07):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[2]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Medical Information,2018,31(07):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[3]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Medical Information,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[4]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Medical Information,2018,31(07):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Medical Information,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Medical Information,2018,31(07):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
　MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Medical Information,2018,31(07):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Medical Information,2018,31(07):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(07):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
　TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Medical Information,2022,35(07):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]

更新日期/Last Update: 2020-04-01